Recovery of Varicella-Zoster Virus-Specific T Cell Immunity after T Cell-Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 12, 2008, Pages 1417-1424

  Distler, Eva ^a   Schnürer, Elke ^a   Wagner, Eva ^a   von Auer, Charis ^a   Plachter, Bodo ^a   Wehler, Daniela ^a   Huber, Christoph ^a   Kolbe, Karin ^a   Meyer, Ralf Georg ^a   Herr, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

ELISPOT; Herpes zoster; Interferon ; T cell depletion; Varicella zoster virus

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOSPORIN A; FAMCICLOVIR; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENGRAFTMENT; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS; VIRUS CARRIER; VIRUS IMMUNITY; VIRUS REACTIVATION;

FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE DEPLETION; MALE; RECOVERY OF FUNCTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VACCINATION; VIRAL VACCINES; VIRUS ACTIVATION;

EID: 56549098945     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.09.004     Document Type: Article

References (23)

1. Gnann Jr. J.W., and Whitley R.J. Herpes zoster. N Engl J Med 347 (2002) 340-346
2. Arvin A.M. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 166 (1992) S35-S41
3. Locksley R.M., Flournoy N., Sullivan K.M., et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 152 (1985) 1172-1181
4. Arvin A.M. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 6 (2000) 219-230
5. Han C.S., Miller W., Haake R., et al. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 13 (1994) 277-283
6. Koc Y., Miller K.B., Schenkein D.P., et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 6 (2000) 44-49
7. Ljungman P., Wilczek H., Gahrton G., et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation response to herpes virus antigens in vitro. Bone Marrow Transplant 1 (1986) 185-192
8. Thomson K.J., Hart D.P., Banerjee L., et al. The effect of low-dose acyclovir on reactivation of varicella zoster virus after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 35 (2005) 1065-1069
9. Boeckh M., Kim H.W., Flowers M.E.D., et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation: a randomized, double-blind, placebo-controlled study. Blood 107 (2006) 1800-1805
10. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110 (2007) 3071-3077
11. Meyers J.D., Flournoy N., and Thomas E.D. Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis 141 (1980) 479-487
12. Kato S., Yabe H., Yabe M., et al. Studies on transfer of varicella-zoster virus-specific T-cell immunity from bone marrow donor to recipient. Blood 75 (1990) 806-809
13. Hata A., Asanuma H., Rinki M., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347 (2002) 26-34
14. Meyer R.G., Britten C.M., Wehler D., et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 109 (2007) 374-382
15. + T lymphocyte responses. Blood 96 (2000) 1857-1864
16. + T cell responses to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 188 (2003) 40-52
17. + T cells after primary infection. J Virol 80 (2006) 9772-9778
18. Abendroth A., Lin I., Slobedman B., et al. Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol 75 (2001) 4878-4888
19. Ljungman P., Lönnqvist B., Gahrton G., et al. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 153 (1986) 840-847
20. Wilson A., Sharp M., Koropchak C.M., et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165 (1992) 119-126
21. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98 (2001) 1358-1364
22. Cwynarski K., Ainsworth J., Cobbold M., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97 (2001) 1232-1240
23. Redman R.L., Nader S., Zerboni L., et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 176 (1997) 578-585